Five things for pharma marketers to know: Thursday, February 11, 2016

Five things for pharma marketers to know: Thursday, February 11, 2016

Copaxone sales fall; Mylan to acquire Swedish drugmaker; health insurers report financial losses from ACA plans

Shannon Hartley, former head of Razorfish Health, joins nonprofit

Shannon Hartley, former head of Razorfish Health, joins nonprofit

She is the first chief marketing officer for Shatterproof.

With support of FDA committee, Remicade biosimilar edges closer to market

With support of FDA committee, Remicade biosimilar edges closer to market

The FDA is set to announce its decision on the drug in April.

IPO filing reveals Cannes Lions makes $59 million in annual revenue

IPO filing reveals Cannes Lions makes $59 million in annual revenue

Lions Health, launched in 2014, generated $1.9 million in revenue last year.

Five things for pharma marketers to know: Wednesday, February 10, 2016

Five things for pharma marketers to know: Wednesday, February 10, 2016

SEC is investigating Salix Pharmaceuticals; FDA adcomm recommends approval of Remicade biosimilar; Medicare considers payment changes

Federal agencies and ad groups join forces for prediabetes campaign

Federal agencies and ad groups join forces for prediabetes campaign

The campaign targets 86 million Americans, 90% of whom aren't aware they have the condition.

Five things for pharma marketers to know: Tuesday, February 9, 2016

Five things for pharma marketers to know: Tuesday, February 9, 2016

The FDA to review biosimilar Remicade; lawmaker looks at panelists' ties to painkiller manufacturers; Novartis signs risk-sharing contracts for Entresto

Startup unveils tools to improve trial reproducibility

Startup unveils tools to improve trial reproducibility

The newly launched tools aim to reduce the time and costs of marketing new drugs by "debugging" the lab environment.

New consumer concerns harder for health brands to swallow

New consumer concerns harder for health brands to swallow

Finicky formulary committees and rising consumer cost consciousness add up to a new market dynamic for health brands. A new survey helps break it down.

Toenail fungus, IBS drugs headline pharma Super Bowl play

Toenail fungus, IBS drugs headline pharma Super Bowl play

It's the industry's biggest turnout in the Super Bowl in three years.

Five things for pharma marketers to know: Monday, February 8, 2016

Five things for pharma marketers to know: Monday, February 8, 2016

PhRMA and BIO ramp up ad spend for presidential election year; Super Bowl Sunday features three pharma ads; Pfizer solidifies leadership team

Five things for pharma marketers to know: Friday, February 5, 2016

Five things for pharma marketers to know: Friday, February 5, 2016

Johnson & Johnson collaborates with biotech on diabetes stem-cell treatment; the FDA warms up to Remicade biosimilar; Woodcock warns about biosimilar backlog

Ascension Health ups Ragone to chief marcomms officer

Ascension Health ups Ragone to chief marcomms officer

The Ketchum veteran joined the nonprofit healthcare system in mid-2014.

House Oversight committee upbraids Turing, Valeant execs

House Oversight committee upbraids Turing, Valeant execs

A House lawmaker called pricing strategies used by Turing and Valeant "repulsive."

Burcin departs Havas network for Klick Health in senior-staffing push

Burcin departs Havas network for Klick Health in senior-staffing push

Burcin's charge is to keep momentum going at the indie agency, known for placing ice-cream carts outside of rival agencies and other recruiting tactics.

Five things for pharma marketers to know: Thursday, February 4, 2016

Five things for pharma marketers to know: Thursday, February 4, 2016

Valeant to push for changes to financial-assistance rules; House to hold hearing on drug-pricing practices; FDA committee says Lundbeck can add information to leaflet

McCann Torre Lazur names new president

McCann Torre Lazur names new president

After Bill McEllen's departure, the company promoted Mark Willmann to lead the agency.

Johnson & Johnson comms leader stepping down

Johnson & Johnson comms leader stepping down

FitzPatrick is departing the company as it evaluates its 150 agency partnerships.

Five things for pharma marketers to know: Wednesday, February 3, 2016

Five things for pharma marketers to know: Wednesday, February 3, 2016

Seven potential blockbusters set to launch in 2016; Amarin case may lead to 'misleading' marketing; Valeant, Turing raised prices to meet preset targets

Orphan drug sales expected to grow 12% by 2020

Orphan drug sales expected to grow 12% by 2020

Click for an infographic to learn more about orphan drugs, rare diseases and the top-selling drugs in the category.

Five things for pharma marketers to know: Tuesday, February 2, 2016

Five things for pharma marketers to know: Tuesday, February 2, 2016

Gleevec generics hit shelves; four OxyContin patents are invalidated; Sanofi axes 600 positions

Dudnyk promotes Tobias to president after Powers

Dudnyk promotes Tobias to president after Powers

Plus other industry hires and changes

The 2016 MM&M Awards is now accepting entries

The 2016 MM&M Awards is now accepting entries

The awards have four new categories: Best Use of Relationship Marketing, Best Use of Data/Analytics, Best Film or Video, and Most Daring Campaign.

Five things for pharma marketers to know: Monday, February 1, 2016

Five things for pharma marketers to know: Monday, February 1, 2016

AbbVie cuts 2016 sales estimate for Viekira Pak; Abbott to acquire Alere for $5.8 billion; Express Scripts to stop covering Valeant's Glumetza

Eli Lilly's diabetes drugs drive sales

Eli Lilly's diabetes drugs drive sales

The pharmaceutical company reported a 2% revenue increase in 2015, and diabetes medication is a key contributor.

Sridhar Iyengar to be keynote speaker at the MM&M Transforming Healthcare Conference

Sridhar Iyengar to be keynote speaker at the MM&M Transforming Healthcare Conference

The Silicon Valley gadget guru who helped define the beyond-the-pill era will talk about embedding nontraditional capabilities into biopharma business models.

BMS CEO defends use of DTC to promote cancer drug

BMS CEO defends use of DTC to promote cancer drug

The drugmaker's CEO said the campaign helps dispel pessimism created from a history of cancer drugs that lack "significant value."

Five things for pharma marketers to know: Friday, January 29, 2016

Five things for pharma marketers to know: Friday, January 29, 2016

FDA approves Merck's HCV doublet regimen; Gilead CEO steps down; Clinton takes aim at Valeant price hikes

Novartis says slow Entresto sales due to limited access

Novartis says slow Entresto sales due to limited access

In many cases, the drug required physicians to request prior authorization.

Five things for pharma marketers to know: Thursday, January 28, 2016

Five things for pharma marketers to know: Thursday, January 28, 2016

Sales of cystic-fibrosis drug Orkambi higher than expected; new sensor tracks sweat; J&J develops clinical trial to find new way to treat depression

Tecfidera's DTC campaign boosts Web traffic and call volume

Tecfidera's DTC campaign boosts Web traffic and call volume

Biogen execs said a recently launched DTC campaign for Tecfidera is showing positive early signs.

InVentiv Health PR promotes O'Kane to MD

InVentiv Health PR promotes O'Kane to MD

Former Biosector 2 US MD Jeanine O'Kane was named inVentiv Health PR Group's US MD.

Five things for pharma marketers to know: Wednesday, January 27, 2016

Five things for pharma marketers to know: Wednesday, January 27, 2016

The FDA plans to release new guidance on advertising in 2016; Trump supports Medicare price negotiations; Novartis CEO: golden days of drug pricing are over

J&J CEO: Patients have higher expectations

J&J CEO: Patients have higher expectations

Faced with slowing sales, the company is in the early stages of developing value-added services that support better patient outcomes.

Johnson & Johnson Baby appoints AKQA as China AOR

Johnson & Johnson Baby appoints AKQA as China AOR

Following November pitch, WPP agency will handle digital strategy, creative and social in region.

Five things for pharma marketers to know: Tuesday, January 26, 2016

Five things for pharma marketers to know: Tuesday, January 26, 2016

The FDA accepts bid for new label for Jardiance; Markey puts on a hold on Califf's FDA nomination; GSK is studying the Zika virus

Five things for pharma marketers to know: Monday, January 25, 2016

Five things for pharma marketers to know: Monday, January 25, 2016

Valeant CEO is recovering; three drugmakers partner for early-stage cancer research

Kantar Health names CEO of Europe

Kantar Health names CEO of Europe

Michel Murino, former CEO of southern Europe and France, will now head the company's regional operations in Europe.

Five things for pharma marketers to know: Friday, January 22, 2016

Five things for pharma marketers to know: Friday, January 22, 2016

NICE recommends Opdivo for skin cancer; Sanofi layoffs could be looming; Senators ask for feedback on Sovaldi investigation

FDA slams Pfizer subsidiary for "misleading" Precedex video

FDA slams Pfizer subsidiary for "misleading" Precedex video

The Office of Prescription Drug Promotion said Hospira, now a Pfizer subsidiary, omitted information and misbranded the drug.

At Work With: Fingerpaint's Joe Acee

At Work With: Fingerpaint's Joe Acee

"A global launch of a type-2 diabetes drug. It was a four-year trail of cheers and tears."

Weber Shandwick reorganizes its healthcare practice

Weber Shandwick reorganizes its healthcare practice

The agency named a new chief strategist and creative director along with new leads for its Minnesota, Chicago and New York healthcare practices.

Five things for pharma marketers to know: Thursday, January 21, 2016

Five things for pharma marketers to know: Thursday, January 21, 2016

GSK CEO says consumer health business could be its own entity; regulatory setbacks cloud future of DMD treatments; OPDP slams YouTube video

Five things for pharma marketers to know: Wednesday, January 20, 2016

Five things for pharma marketers to know: Wednesday, January 20, 2016

Part of drugmakers' sales growth stems from price increases; AbbVie's Venetoclax gets second Breakthrough designation; two states in India stop Avastin sales

Medical publishers eye new ad viewability rules

Medical publishers eye new ad viewability rules

They will attempt to develop a new industry standard for digital advertising viewability, a much debated topic that has vexed the broader advertising industry.

Pharma marketing agencies merge to form Aventria Health Group

Pinnacle Health Communications and Franklyn Healthcom merge to offer "more complete" customer-centric solutions.

Five things for pharma marketers to know: Tuesday, January 19, 2016

Five things for pharma marketers to know: Tuesday, January 19, 2016

Government pressure can influence drug-pricing decisions; Samsung's biosimilar version of Enbrel is approved in Europe; J&J to cut jobs in medical-devices business

Pharma companies turn to LinkedIn to engage

Pharma companies turn to LinkedIn to engage

Part of LinkedIn's appeal lies in the high level of engagement of its members and the potential for precise targeting of content and talent searches.

Five things for pharma marketers to know: Friday, January 15, 2016

Five things for pharma marketers to know: Friday, January 15, 2016

The FDA declines to approve two drugs for Duchenne muscular dystrophy; government watchdog questions FDA's post-market drug tracking; WebMD denies acquisition talks

Healthline Media receives $95 million in equity funding

Healthline Media receives $95 million in equity funding

Summit Partners' investment in the health information site expected to aid the company's efforts to compete with sites like WebMD

How pharma can stay competitive in the digital world

How pharma can stay competitive in the digital world

Drugmakers seeking to develop "beyond-the-pill" digital initiatives have to be willing to engage patients in new ways, McKinsey & Company report finds.

Five things for pharma marketers to know: Thursday, January 14, 2016

Five things for pharma marketers to know: Thursday, January 14, 2016

Valeant is "uncertain" when CEO will return; Bayer hires Razorfish and iCrossing for digital; more drugmakers that sell hemophilia drugs are hiring patients

Five things for pharma marketers to know: Wednesday, January 13, 2016

Five things for pharma marketers to know: Wednesday, January 13, 2016

Biden to lead "moonshot" to cure cancer; Pfizer/Allergan merger to create "best pipeline in the industry," CEO says; AMA invests in health tech startup

Former Greyhealth and CDM executives launch Minds + Assembly

Former Greyhealth and CDM executives launch Minds + Assembly

The healthcare agency debuts with Swedish-based pharma company Orexo as its first client.

Senate committee clears Califf as FDA head

Senate committee clears Califf as FDA head

Two senators, including presidential candidate Bernie Sanders, threatened to hold up his nomination.

New multiple myeloma drugs prompt cost-effectiveness report

New multiple myeloma drugs prompt cost-effectiveness report

The FDA in November approved three new drugs that treat the rare blood cancer.

Five things for pharma marketers to know: Tuesday, January 12, 2016

Five things for pharma marketers to know: Tuesday, January 12, 2016

HCPs sound off on CMS opioid proposal; Senate committee to decide if Califf gets FDA commissioner nod; Celgene names new CEO

McCann HumanCare names Mazzola as EVP, group creative director

McCann HumanCare names Mazzola as EVP, group creative director

Mazzola says healthcare advertising is having a watershed moment.

Five things for pharma marketers to know: Monday, January 11, 2016

Five things for pharma marketers to know: Monday, January 11, 2016

Shire buys Baxalta, creates world's largest rare-disease drugmaker; drug prices continue to climb; immunotherapy coalition is formed

7 takeaways from StartUp Health's annual report

7 takeaways from StartUp Health's annual report

The digital health sector brought in an estimated $6 billion in funding in 2015.

Sanofi promotes Loew to lead global commercial operations

Sanofi promotes Loew to lead global commercial operations

Damian Braga, who held the role previously, retired after 27 years working for the drugmaker

Five things for pharma marketers to know: Friday, January 8, 2016

Five things for pharma marketers to know: Friday, January 8, 2016

GSK will stop using outside doctors to promote its drugs; Roche will file its immuno-oncology drug for approval; Mylan inks deal to develop six biosimilars

Five things for pharma marketers to know: Thursday, January 7, 2016

Five things for pharma marketers to know: Thursday, January 7, 2016

Fitbit faces allegations of inaccurate heart monitoring; Viiv Healthcare to collaborate with Janssen; Guardant Health raises funding for its cancer blood tests

Weber Shandwick buys healthcare specialist ReviveHealth

Weber Shandwick buys healthcare specialist ReviveHealth

Nashville-based ReviveHealth posted $8.7 million in revenue in 2014.

Millennials advocate for technology and promotion at agencies but are slow to take risks

Millennials advocate for technology and promotion at agencies but are slow to take risks

Millennials at pharma agencies are driven and tech-savvy but also pay too much attention to promotion and the shape of their careers, say agency leaders.

Roche invests in oncology start-up

Roche invests in oncology start-up

The drugmaker led a Series C fundraising round totaling $175 million. The funding will be used to accelerate clinical trials.

Five things for pharma marketers to know: Wednesday, January 6, 2016

Five things for pharma marketers to know: Wednesday, January 6, 2016

Lilly's Jardiance starting to gain market share; Merck "raring" to make acquisitions; Sanofi said it will stop marketing Afrezza

Sanofi to stop marketing Afrezza, citing low Rx

Sanofi to stop marketing Afrezza, citing low Rx

Sanofi spent $3.75 million on advertising for Afrezza in the third quarter of 2015 yet the therapy only brought in about $2 million in revenue.

4A's announces plans to defend DTC

4A's announces plans to defend DTC

The American Association of Advertising Agencies said stopping calls for a ban on DTC is a top agenda item for the trade group in 2016.

Five things for pharma marketers to know: Tuesday, January 5, 2016

Five things for pharma marketers to know: Tuesday, January 5, 2016

Gilead's hep-C combo gets Breakthrough designation; Baxalta licences experimental cancer drugs; Novartis agrees to settle class-action lawsuit

Infographic: more on MM&M's Transformers

Infographic: more on MM&M's Transformers

As students, about 27% of MM&M's healthcare transformers received degrees in subjects that did not include health, business or technology.

Q&A: Why McCann Health set up a pharmacy focused agency

Q&A: Why McCann Health set up a pharmacy focused agency

A Q&A with Sandra Carey, president of the McCann Pharmacy Initiative, on the move to push pharmacy to the forefront.

Five things for pharma marketers to know: Monday, January 4, 2016

Five things for pharma marketers to know: Monday, January 4, 2016

The FDA approved 45 new drugs in 2015; Baxalta signs immuno-oncology deal; pharma M&A activity may slow this year

ICC and Pace merge, renamed Cure

ICC and Pace merge, renamed Cure

FCB Health opted to merge the two agencies and rebrand their US shops, which together plan to fill 40 open positions in 2016.

Five things for pharma marketers to know: Thursday, December 31, 2015

Five things for pharma marketers to know: Thursday, December 31, 2015

Generic Nexium will be blue; researcher says scientific papers should be anonymous; patients with health insurance still struggle to cover the costs of drugs

ACCME, PharmedOut spar over CME money

ACCME, PharmedOut spar over CME money

The main accreditation body for CME activities traded barbs with an academic critic over courses designed to enlighten doctors about hypoactive sexual desire disorder.

Five things for pharma marketers to know: Wednesday, December 30, 2015

Five things for pharma marketers to know: Wednesday, December 30, 2015

Twenty percent of publicly funded cancer clinical trials don't enroll enough patients; KaloBios files for bankruptcy; a new MS campaign in Australia uses bicycles

WPP's Sudler & Hennessey acquires majority stake in System Analytic

The healthcare marketing and communications network aims to bolster its offering for the drug industry's growing demand for KOL engagement.

Stat may be just what the doctor ordered

Stat may be just what the doctor ordered

Rick Berke, executive editor of Stat, talks about the title's strategy to make health, medicine and life sciences content compelling and deliver this news to a general audience.

Chase joins Makovsky as chief digital officer

Chase joins Makovsky as chief digital officer

The new chief digital officer at Makovsky, Justin Chase, says the client-customer relationship in healthcare has fundamentally changed.

Five things for pharma marketers to know: Tuesday, December 29, 2015

Five things for pharma marketers to know: Tuesday, December 29, 2015

Generic-drug approval backlog criticized; KaloBios board members step down; Sovaldi costs as little as $4 in India

Five things for pharma marketers to know: Monday, December 28, 2015

Five things for pharma marketers to know: Monday, December 28, 2015

Valeant CEO takes medical leave; average asthma rates for US children trends downward; drugmakers paid $7 billion for coupons and co-pay cards in 2015

Editor's choice: your favorite campaigns of 2015

Editor's choice: your favorite campaigns of 2015

Campaigns around opioid abuse, lung cancer drugs and women's health took the spotlight in 2015.

Five things for pharma marketers to know: Wednesday, December 23, 2015

Five things for pharma marketers to know: Wednesday, December 23, 2015

Clinton calls for Alzheimer's funding; an FDA approval of an older drug may mean higher prices; the FDA approves AstraZeneca's gout drug

The year's top pharma marketing controversies

The year's top pharma marketing controversies

Drug pricing is easily the biggest controversy but pharma faced other issues, too, like the AMA's call to ban DTC advertising.

Precision for Medicine receives $75 million investment

Private equity firm TPG Growth invested in the healthcare services company, which plans to use the funds to expand its capabilities and reach.

DCI Group aids Turing amid drug price, Shkreli controversies

DCI Group aids Turing amid drug price, Shkreli controversies

The firm began working with the pharma company before outrage over its drug pricing but has more recently supported the client after former CEO Martin Shkreli was arrested.

Five things for pharma marketers to know: Tuesday, December 22, 2015

Five things for pharma marketers to know: Tuesday, December 22, 2015

Valeant says it lost few reps despite business scrutiny; Novartis CEO says drugmakers must share benefits of new medicines with other healthcare stakeholders; Bloomberg analysis finds US pays more for branded drugs after discounts

Our most read agency stories of 2015

Our most read agency stories of 2015

Mergers, acquisitions and reorganizations among pharma agencies piqued your interest in 2015.

Five things for pharma marketers to know: Monday, December 21, 2015

Five things for pharma marketers to know: Monday, December 21, 2015

Shkreli resigns from Turing; Keytruda approved as first-line melanoma treatment; drugmakers seek to fend off California pricing ballot initiative

Our most read stories of 2015

An award-winning campaign about talking fish; the OTC switch for GlaxoSmithKline's Flonase; a direct-to-consumer push for Afrezza, Sanofi's and MannKind's inhaled insulin

A legendary letter: Bill Bernbach's 1940s plea for creativity

A legendary letter: Bill Bernbach's 1940s plea for creativity

The note is exceptional not merely for its passion—Bernbach admits to being "damned worried" about the agency's future—but for its historical resonance.

Five things for pharma marketers to know: Friday, December 18, 2015

Five things for pharma marketers to know: Friday, December 18, 2015

GlaxoSmithKline buys Bristol-Myers Squibb's research assets; Gilead Sciences makes large stake in experimental rheumatoid arthritis drug; Avandia's REMS program ends

Lantus competitor receives FDA approval

Lantus competitor receives FDA approval

Eli Lilly and Boehringer Ingelheim received approval to begin selling their Lantus knock-off drug after settling a patent lawsuit with Sanofi in September.

Pfizer and Allergan merger to create uncertainty for agencies, execs say

Pfizer and Allergan merger to create uncertainty for agencies, execs say

The deal not only creates the world's largest drugmaker but also one of the world's largest advertisers.

Five things for pharma marketers to know: Thursday, December 17, 2015

Five things for pharma marketers to know: Thursday, December 17, 2015

The FDA approves Lilly's Lantus follow-on biologic; AstraZeneca buys majority stake in Acerta Pharma; Shkreli arrested on securities fraud charges

Five things for pharma marketers to know: Wednesday, December 16, 2015

Five things for pharma marketers to know: Wednesday, December 16, 2015

Britain says Bristol-Myers Squibb's Opdivo is too expensive; Calpers reports 32% boost in specialty drug spending; NIH is funding fewer clinical trials

The FDA settles with Pacira, rescinds warning letter

The FDA settles with Pacira, rescinds warning letter

The FDA withdrew a 2014 warning letter related to Pacira Pharmaceuticals' marketing of its painkiller Exparel as part of a settlement reached by both parties this week.

Urhekar, in biggest move yet as Americas president, unites McCann Health NA agencies

Urhekar, in biggest move yet as Americas president, unites McCann Health NA agencies

IPG's McCann Health announces branding and operational changes aimed at integrating its US and Canadian shops.

Five things for pharma marketers to know: Tuesday, December 15, 2015

Five things for pharma marketers to know: Tuesday, December 15, 2015

Valeant agrees to cut prices in deal with Walgreens; FDA committee votes against Merck's Vytorin claims; Pacira settles off-label marketing case with the FDA

Email Newsletters